iCan:Israel-Cannabis to Bring FDA Approved Nebulizers to the Medical Cannabis Market
TEL AVIV, Israel, Dec. 12, 2017 /PRNewswire/ — iCAN:Israel-Cannabis and Aura Medical have joined forces to bring FDA approved nebulizers to the burgeoning medical cannabis market.
The Aura’s Portable Nebulizer is widely acclaimed and recommended by the nation’s top Pulmonologists and Respiratory Therapists for use in treating asthma and COPD and now will be used by millions more worldwide. The device will be marketed under the brand name “Nebican”.
Utilizing specially developed controlled dosages, the Nebican portable nebulizer is a perfect delivery system for medical cannabis. Nebican is the answer to medical practitioners and patients worldwide as demand turns towards medical cannabis to alleviate numerous ailments.
Designed with patented Vibrating Mesh Technology (VMT), Nebican is an innovative form of atomization that emits extremely thin and fog like vapor. Like air, the mist released from the inhaler can easily penetrate deep into the lungs. Pocket sized, it is portable, discreet, convenient and easy to use.
“We are proud to pair our unique delivery platform, that until now been used for prescription medications including Albuterol®, Pulmicort Respules®, DuoNeb® Intal and others, with targeted formulation from Ci Therapeutics,” said Connie Lefkowitz, CEO of Aura Medical.
Ci Therapeutics, (an iCAN & CannRX partnership) has significantly progressed on its validation of ican.sleep, an advanced cannaceutical to be delivered on the Nebican inhalation platform.
Nebican & ican.sleep are expected to launch in California in mid-2018 with the Canadian market to follow.
“This is a game changer, taking an advanced pulmonary FDA approved delivery platform and formulating a sleep product to deliver safe cannabis in a doseable and repeatable way,” said iCAN: Israel-Cannabis Founder and CEO, Saul Kaye.
About Aura Medical
Aura Medical was founded in 2013 by a team of scientists, medical professionals, and business advisors with a mission to bring respiratory devices into the 21st century. With over 50 years of combined clinical experience Aura Medical designs and develops cutting edge respiratory devices. As the numbers of Asthma, COPD and respiratory disease sufferers rise dramatically each year, Aura Medical will join them in the fight for their breath.
About Ci Therapeutics
Ci Therapeutics is an innovative cannabis company dedicated to bringing advanced cannabis formulations to market. The initial product, ican.sleep will use the Nebican to help people get a good night’s sleep. This will become a platform of formulations delivering advanced, clinically validated, unique formulations on pharmaceutical grade delivery systems.
Ci Therapeutics is a joint venture between iCAN and CannRx.
About CannRx Technology
CannRx has developed highly accurate quantitative and qualitative analytical chemical assays as well as disease-specific bioassays to determine the activity of specific cannabinoids in the cannabis plant. CannRx has also designed unique and proprietary delivery systems for medical cannabis that increase bioavailability, reduce carcinogenicity, and provide precise dosing of cannabis-based medicines. Its technology provides the benefit of lower doses with increased and prolonged effects with a reduction of side effects.
iCAN is a globally recognized Israeli company focused on the medical cannabis industry. iCAN operates across all verticals including: consulting, business development, mentoring, investment strategy, network and media, compliance and regulation, CRO, commercialization, formulation and international distribution.
This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical facts may be deemed forward looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “to,” “plan,” “expect,” “believe,” “anticipate,” “intend,” “could,” “should,” “would,” “estimate,” or “continue,” or the negative or other variations thereof or comparable terminology are intended to identify forward looking statements.
Investors are cautioned that all forward looking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing or issues relating to manufacturing capacity; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement relating to product liability, patent protection, governmental investigations, and other legal proceedings; the Company’s ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals; any changes in business, political and economic conditions; business interruption due to hurricanes or other events outside of the Company’s control.
Investors are cautioned not to place reliance on these forward looking statements, which are valid only as of the date they were made. The Company undertakes no obligation to update or revise any forward looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.